These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 24782985)

  • 61. Immunogenic Apoptotic Cell Death and Anticancer Immunity.
    Vandenabeele P; Vandecasteele K; Bachert C; Krysko O; Krysko DV
    Adv Exp Med Biol; 2016; 930():133-49. PubMed ID: 27558820
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunogenic Cell Death Induction by Ionizing Radiation.
    Zhu M; Yang M; Zhang J; Yin Y; Fan X; Zhang Y; Qin S; Zhang H; Yu F
    Front Immunol; 2021; 12():705361. PubMed ID: 34489957
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenic Cell Death in Cancer Therapy.
    Troitskaya OS; Novak DD; Richter VA; Koval OA
    Acta Naturae; 2022; 14(1):40-53. PubMed ID: 35441043
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy.
    Radogna F; Diederich M
    Biochem Pharmacol; 2018 Jul; 153():12-23. PubMed ID: 29438676
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor.
    Jiang Q; Zhang C; Wang H; Peng T; Zhang L; Wang Y; Han W; Shi C
    Front Oncol; 2019; 9():1196. PubMed ID: 31781498
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunodominant AH1 Antigen-Deficient Necroptotic, but Not Apoptotic, Murine Cancer Cells Induce Antitumor Protection.
    Aaes TL; Verschuere H; Kaczmarek A; Heyndrickx L; Wiernicki B; Delrue I; De Craene B; Taminau J; Delvaeye T; Bertrand MJM; Declercq W; Berx G; Krysko DV; Adjemian S; Vandenabeele P
    J Immunol; 2020 Feb; 204(4):775-787. PubMed ID: 31900335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunogenic cell death modalities and their impact on cancer treatment.
    Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
    Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The Concept of Immunogenic Cell Death in Antitumor Immunity].
    Fučíková J; Bartůňková J; Špíšek R
    Klin Onkol; 2015; 28 Suppl 4():4S48-55. PubMed ID: 26647889
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunogenic cell death in cancer immunotherapy.
    Choi M; Shin J; Lee CE; Chung JY; Kim M; Yan X; Yang WH; Cha JH
    BMB Rep; 2023 May; 56(5):275-286. PubMed ID: 37081756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer.
    Fucikova J; Kasikova L; Truxova I; Laco J; Skapa P; Ryska A; Spisek R
    Immunol Lett; 2018 Jan; 193():25-34. PubMed ID: 29175313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
    Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
    J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy.
    Son KJ; Choi KR; Lee SJ; Lee H
    Immune Netw; 2016 Feb; 16(1):75-84. PubMed ID: 26937234
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genetic modification of oncolytic viruses to enhance antitumor immunity.
    Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
    Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibitory DAMPs in immunogenic cell death and its clinical implications.
    Hayashi K; Nikolos F; Chan KS
    Cell Stress; 2021 Mar; 5(4):52-54. PubMed ID: 33821233
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
    Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
    J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.
    Montico B; Nigro A; Casolaro V; Dal Col J
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.